...
首页> 外文期刊>Internal medicine. >Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma
【24h】

Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma

机译:在成人T细胞白血病/淋巴瘤的患者中均匀治疗腹水保留

获取原文
获取原文并翻译 | 示例
           

摘要

A 74-year-old woman with refractory adult T-cell leukemia/lymphoma (ATLL) received three courses of mogamulizumab. Despite obtaining complete remission, she thereafter presented with progressive ascites. An analysis of the ascites and laboratory tests revealed no evidence of ATLL invasion, infectious disease, or liver cirrhosis. The mogamulizumab concentrations were maintained in the ascites at approximately 10-15% of that in the plasma. Mogamulizumab was considered to be a plausible pathogenesis of her ascites. To the best of our knowledge, this is the first report suggesting mogamulizumab-induced ascites.
机译:一个74岁的女性,难治性成人T细胞白血病/淋巴瘤(ATLL)接受了三种萌芽的萌芽。 尽管获得了完全的缓解,但后者呈现出渐进腹水。 对腹水和实验室测试的分析显示没有ATLL入侵,传染病或肝硬化的证据。 将摩利甘露花浓度的浓度保持在腹水中的约10-15%在血浆中。 Mogamulizumab被认为是她腹水的合理发病机制。 据我们所知,这是第一份提出Mogamulizumab引起的腹水的报告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号